First Citizens Financial Corp lessened its position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 1.6% in the third quarter, Holdings Channel reports. The fund owned 3,608 shares of the company’s stock after selling 58 shares during the quarter. Eli Lilly and Company comprises 1.7% of First Citizens Financial Corp’s investment portfolio, making the stock its 18th biggest holding. First Citizens Financial Corp’s holdings in Eli Lilly and Company were worth $3,196,000 as of its most recent SEC filing.
A number of other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in shares of Eli Lilly and Company by 1.6% in the first quarter. Vanguard Group Inc. now owns 72,745,011 shares of the company’s stock worth $56,592,709,000 after buying an additional 1,133,810 shares during the last quarter. Capital Research Global Investors raised its position in Eli Lilly and Company by 6.0% in the first quarter. Capital Research Global Investors now owns 8,031,531 shares of the company’s stock worth $6,248,210,000 after acquiring an additional 453,939 shares during the period. Capital International Investors boosted its stake in shares of Eli Lilly and Company by 5.1% during the 1st quarter. Capital International Investors now owns 6,972,393 shares of the company’s stock worth $5,424,243,000 after acquiring an additional 335,560 shares during the last quarter. Fisher Asset Management LLC grew its position in shares of Eli Lilly and Company by 1.9% during the 4th quarter. Fisher Asset Management LLC now owns 4,542,089 shares of the company’s stock valued at $2,647,675,000 after acquiring an additional 85,015 shares during the period. Finally, GQG Partners LLC increased its stake in shares of Eli Lilly and Company by 20.2% in the 1st quarter. GQG Partners LLC now owns 3,848,886 shares of the company’s stock worth $2,994,280,000 after purchasing an additional 648,094 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.
Insiders Place Their Bets
In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 210,000 shares of the company’s stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total transaction of $197,362,200.00. Following the completion of the transaction, the insider now directly owns 96,943,810 shares in the company, valued at $91,109,731,514.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.13% of the company’s stock.
Wall Street Analysts Forecast Growth
View Our Latest Stock Analysis on Eli Lilly and Company
Eli Lilly and Company Price Performance
NYSE:LLY opened at $885.15 on Friday. The firm’s fifty day moving average is $898.50 and its two-hundred day moving average is $846.49. The firm has a market cap of $841.25 billion, a price-to-earnings ratio of 130.36, a PEG ratio of 2.78 and a beta of 0.42. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. Eli Lilly and Company has a one year low of $523.63 and a one year high of $972.53.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.64 by $1.28. The business had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. Research analysts expect that Eli Lilly and Company will post 16.49 EPS for the current year.
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Recommended Stories
- Five stocks we like better than Eli Lilly and Company
- How to Use the MarketBeat Dividend Calculator
- Beat the Volatility: Top 3 Low-Beta Stocks to Watch
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Visa and Mastercard: Top Payment Stocks to Watch After Rate Cuts
- Why Invest in 5G? How to Invest in 5G Stocks
- When Is the Best Time to Invest in Mutual Funds?
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.